scholarly journals Overview of Glucose Levels, Blood Pressure, and Lipid Profiles in Patients with Prolanis DM Hypertension

2021 ◽  
Vol 2 (2) ◽  
pp. 61-67
Author(s):  
Hening Imawati
Keyword(s):  
Blood Pressure ◽  
Blood Glucose ◽  
Lipid Profile ◽  
Normal Blood ◽  
Primary Data ◽  
Service Program ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
High Lipid ◽  
Research Type

The Primary Clinic of UKSW is one of the FKTP BPJS Health implementing service program of chronic disease (Prolanis). Patients with screening of one time blood glucose 200 mg/dL or fasting blood sugar 126 mg/dL were included in control patients of DM prolanis. Patients with criteria of pre hypertension and hypertension 1 were included in the control patients of hypertensive prolanis. Patients with DM and hypertension may have level of high lipid profile so laboratory tests are needed to prevent complications, including cholesterol, HDL, LDL and triglycerides. Research objective to find out the description of glucose level, blood pressure, and lipid profile in patients of DM hipertension prolanis at the Primary Clinic of UKSW Salatiga. The research type was descriptive. The research data was primary data by measuring blood pressure, blood glucose levels and lipid profile. Research results normotension 16 (30,2%), pre hypertension 20 (37,70%), and first degree hypertension as many as 17 (32,10%). The glucose levels of normal blood 20 (37,74%), normal 33 (62,26%). The profile levels of normal lipid cholesterol 30 (54,72%), HDL 26 (49,06%), LDL 9 (18,98%), and triglyceride 30 (56,60%). The profile levels of abnormal lipid cholesterol 29 (45,29%), HDL 27 (50,95%), LDL 44 (83,02%), and triglyceride 23 (43,40%). The glucose levels of normal blood 20 (37,74%) in normotension 5 (9,4%), pre hypertension 8 (15,09%), and first degree hypertension as many as 7 (13,21%). Blood glucose levels normal 62,3% in normotension 11 (20,8%), pre hypertension 12 (22,64%) and first degree hypertension as many as 10 (18,87%).

Evaluation of Glucose and Lipid Lowering Activity of Arganimide A in Normal and Streptozotocin-Induced Diabetic Rats

2019 ◽  
Vol 19 (4) ◽  
pp. 503-510 ◽  
Author(s):  
Mohamed Eddouks ◽  
Farid Khallouki ◽  
Robert W. Owen ◽  
Morad Hebi ◽  
Remy Burcelin
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Oral Administration ◽  
Lipid Profile ◽  
Plasma Cholesterol ◽  
Diabetic Rats ◽  
Lipid Lowering ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Lowering Activity

Aims: Arganimide A (4,4-dihydroxy-3,3-imino-di-benzoic acid) is a compound belonging to a family of aminophenolics found in fruit of Argania spinosa. The purpose of this study was to investigate the glucose and lipid lowering activity of Arganimide A (ARG A). Methods: The effect of a single dose and daily oral administration of Arganimide A (ARG A) on blood glucose levels and plasma lipid profile was tested in normal and streptozotocin (STZ) diabetic rats at a dose of 2 mg/kg body weight. Results: Single oral administration of ARG A reduced blood glucose levels from 26.50±0.61 mmol/L to 14.27±0.73 mmol/L (p<0.0001) six hours after administration in STZ diabetic rats. Furthermore, blood glucose levels were decreased from 5.35±0.30 mmol/L to 3.57±0.17 mmol/L (p<0.0001) and from 26.50±0.61 mmol/L to 3.67±0.29 mmol/L (p<0.0001) in normal and STZ diabetic rats, respectively, after seven days of treatment. Moreover, no significant changes in body weight in normal and STZ rats were shown. According to the lipid profile, the plasma triglycerides levels were decreased significantly in diabetic rats after seven days of ARG treatment (p<0.05). Moreover, seven days of ARG A treatment decreased significantly the plasma cholesterol concentrations (p<0.001). Conclusion: ARG A possesses glucose and lipid-lowering activity in diabetic rats and this natural compound may be beneficial in the treatment of diabetes.

scholarly journals ASSOCIATION BETWEEN BLOOD LIPID PROFILE AND BLOOD GLUCOSE LEVELS IN MEN WITH CORONARY HEART DISEASE, METABOLIC SYNDROME, AND TYPE 2 DIABETES MELLITUS

2013 ◽  
Vol 12 (5) ◽  
pp. 29-33
Author(s):  
S. A. Matveeva
Keyword(s):  
Blood Glucose ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Lipoprotein Cholesterol ◽  
Blood Lipid Profile ◽  
Glucose Levels ◽  
Blood Glucose Levels

Aim.To study the associations between blood lipid profile and blood glucose levels in men with coronary heart disease (CHD), stable effort angina (SEA), metabolic syndrome (MS), and Type 2 diabetes mellitus (DM-2).Material and methods.The study included 82 men (mean age 50,5±0,9 years) with CHD, Functional Class I–III SEA, MS, and DM-2. The following lipid profile parameters were assessed: total cholesterol (TCH), triglycerides (TG), low-density lipoprotein cholesterol (LDL–CH), very low-density lipoprotein cholesterol (VLDL–CH), high-density lipoprotein cholesterol (HDL–CH), atherogenic index (AI), and triglyceride index (TGI), together with fasting blood glucose.Results.There were positive (direct) associations between higher levels (>90th percentile) of lipid profile parameters (TCH, TG, LDL–CH, VLDL– CH, HDL–CH, AI, TGI) and blood glucose, as well as between lower levels (≤10th percentile) of lipid profile parameters (TCH, TG, LDL–CH, VLDL– CH, AI, TGI) and blood glucose. At the same time, there were negative (inverse) associations between lower lipid levels (≤10th percentile of TCH, TG, LDL–CH, VLDL–CH, HDL–CH, AI, TGI) and higher glucose levels (>90th percentile), as well as between higher lipid levels (>90th percentile of TCH, TG, LDL–CH, VLDL–CH, HDL–CH, AI, TGI) and lower glucose levels (≤10th percentile).Conclusion.Dyslipidemia and hyperglycemia demonstrate synergetic proatherogenic effects in patients with CHD, SEA, MS, and DM-2, as suggested by significant heterogeneous (direct and inverse) associations between lipid profile parameters and fasting blood glucose. The results obtained provide an opportunity for the assessment of risk levels, prognosis, and need for pharmacological prevention and treatment in patients with combined cardiovascular pathology. 

scholarly journals POLYCYSTIC OVARIAN SYNDROME;

2012 ◽  
Vol 19 (06) ◽  
pp. 786-788
Author(s):  
KIRAN BUTT ◽  
FARAH DEEBA ◽  
HAVAIDA ATTIQUE
Keyword(s):  
Blood Glucose ◽  
Lipid Profile ◽  
Glucose Level ◽  
Fasting Blood Glucose ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Increased Risk ◽  
Commercial Kits ◽  
The University ◽  
Ovarian Syndrome

Objective: The objective of the present study was to determine the changes in the glucose level and lipid profile in patients withpolycystic ovarian syndrome (PCOS). Study Design: Descriptive study. Place and Duration of the study: This study was conducted atInstitute of Molecular Biology and Biotechnology, The University of Lahore from June 2009 to June 2010. Patients and Methods: Total 50patients with PCOS were included and 50 age-matched control subjects were also selected for comparison. Their glucose levels and lipidprofile were assessed using commercial kits. The data thus obtained was subjected to statistical analysis. Results: Significant differences(P<0.05) in fasting blood glucose level and individual parameters of lipid profile were observed in women with PCOS. A higher prevalence ofhypertriglyceridemia, hypercholesterolemia, higher LDL, lower HDL and higher fasting blood glucose levels was explored in PCOS womenthan controls. Conclusions: Abnormal glucose level and lipid profile in PCOS women showed that these women are at an increased risk ofdeveloping diabetes and subsequently cardiovascular diseases.

Effectiveness of acarbose in treating elderly patients with diabetes with postprandial hypotension

2017 ◽  
Vol 65 (4) ◽  
pp. 772-783 ◽  
Author(s):  
Jie Zhang ◽  
Lixin Guo
Keyword(s):  
Blood Pressure ◽  
Blood Glucose ◽  
Elderly Patients ◽  
Controlled Trial ◽  
Clinical Trial Registry ◽  
Postprandial Hypotension ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Patients With Diabetes ◽  
Group B

Postprandial hypotension (PPH) is a common condition that occurs primarily in elderly patients with type 2 diabetes mellitus (T2DM). This study aimed to assess the effectiveness of acarbose for PPH; it also investigated possible mechanisms behind PPH development. This single-blind, randomized controlled trial included 91 elderly patients with T2DM, aged between 60 and 80 years, who were inpatients at Beijing Hospital between March 2012 and November 2014. The patients were included into one of three groups: Group A, patients with T2DM without PPH; Group B, patients with T2DM with PPH receiving placebo; and Group C, patients with T2DM with PPH receiving acarbose. After an overnight fast, patients received a single dose of acarbose (100 mg) or placebo and then consumed a standardized 450 kcal meal. Blood pressure, glucose levels, heart rate (HR), and catecholamine levels were evaluated. Acarbose ameliorated PPH as determined by significant improvements in the duration and maximal fall in blood pressure (both p<0.001); however, no differences in HR and blood glucose levels were observed. In patients with PPH, blood pressure was correlated with blood glucose and HR variability values (p<0.05). Correlations between epinephrine and glucagon-like peptide-1 with blood pressure in groups A and C were largely lost in group B. Acarbose reduced postprandial blood pressure fluctuations in elderly patients with diabetes. PPH may be related to impaired autonomic nervous system function, reduced catecholamine secretion, and postprandial fluctuations in blood glucose levels.Trial registration numberChinese Clinical Trial Registry ChiCTR-IPR-15006177.

scholarly journals The Beneficial Effects of SesaVitaTM on Lipid Profiles and Blood Glucose Levels in Subjects With Prediabetes and Mild-To-Moderate Hyperlipidemia in India

2013 ◽  
Vol 2 (5) ◽  
pp. 104 ◽  
Author(s):  
H. N. Shivaprasad ◽  
M. Bhanumathy ◽  
Ceyhun Tamer ◽  
G. Sushma ◽  
K. R. Raveendra ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Lipid Profile ◽  
Lifestyle Changes ◽  
Secondary Outcome ◽  
Oral Glucose ◽  
Double Blind Study ◽  
Beneficial Effects ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Normal Ranges

<p>Individuals suffering from Type 2 diabetes develop prediabetes before progression of diabetes. In case of prediabetes people, the blood glucose levels are higher than normal but not sufficient to be diagnosed as diabetes. On the basis of existing reports on Sesame extract, SesaVita<sup>TM</sup> which is an herbal food supplement containing Sesame seeds (<em>Sesamum indicum</em> L.) extract may provide an option for management of prediabetes. The objective of this study was to determine the beneficial effects of SesaVita<sup>TM</sup> in prediabetes and mild to moderate hyperlipidemia subjects. This randomized, placebo-controlled, double-blind study comprised of 13 female and 07 male patients with prediabetes and mild to moderate hyperlipidemia, aged between 18 and 65 years. Twenty subjects were randomized to receive SesaVita<sup>TM</sup> (500 mg/day) or placebo along with therapeutic lifestyle changes for 6 weeks. The primary outcome was the measure of efficacy in terms of change in serum lipid profile and glycaemic levels on week 3 and 6. Secondary outcome measures include safety and tolerability evaluated by physical examination and clinical laboratory evaluations. Improvements in lipid profile and glycaemic levels were observed in SesaVita<sup>TM</sup> treated group when compared with placebo and baseline. A statistical significant reduction was observed in low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), oral glucose tolerance test (OGTT) and fasting blood sugar (FBS) levels during week 3 and 6 when treated with SesaVita<sup>TM</sup> extract.<em> </em>No adverse events occurred and all safety parameters were within normal ranges during the study. This study revealed that the treatment with SesaVita<sup>TM</sup> was safe and well tolerated;<em> </em>may be beneficial in the management of prediabetes and mild-to-moderate hyperlipidemia.</p>

Sign in / Sign up

Export Citation Format

Share Document